Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Monoclonal antibody or fragment thereof
Reexamination Certificate
2008-04-21
2010-02-02
Gambel, Phillip (Department: 1644)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Monoclonal antibody or fragment thereof
C424S130100, C424S133100, C424S141100, C424S153100, C424S173100, C424S094200, C424S094630, C424S094640, C514S822000, C530S387100, C530S387300, C530S388100, C530S388200, C530S388220, C530S388700
Reexamination Certificate
active
07655230
ABSTRACT:
A method for improving clinical outcome in focal ischemic stroke in a mammal by increasing cerebral blood flow and/or reducing infarct size is described which involves administering an effective amount of an anti-CD18 antibody to the mammal, in the absence of removal of the arterial obstruction.
REFERENCES:
patent: 4797277 (1989-01-01), Arfors
patent: 4840793 (1989-06-01), Todd, III et al.
patent: 4935234 (1990-06-01), Todd, III et al.
patent: 5002869 (1991-03-01), Schlossman et al.
patent: 5071964 (1991-12-01), Dustin et al.
patent: 5147637 (1992-09-01), Wright et al.
patent: 5322699 (1994-06-01), Wright et al.
patent: 5914112 (1999-06-01), Bednar et al.
patent: 7361344 (2008-04-01), Bednar et al.
patent: A-15518/88 (1988-11-01), None
patent: 2008368 (1991-06-01), None
patent: 289949 (1988-11-01), None
patent: 346078 (1989-12-01), None
patent: 379904 (1990-08-01), None
patent: 387668 (1990-09-01), None
patent: 438312 (1991-07-01), None
patent: 440351 (1991-08-01), None
patent: WO 90/10652 (1990-09-01), None
patent: WO 90/15076 (1990-12-01), None
patent: WO 91/16927 (1991-11-01), None
patent: WO 91/16928 (1991-11-01), None
patent: WO 91/18011 (1991-11-01), None
patent: WO 91/19511 (1991-12-01), None
patent: WO 92/22323 (1992-12-01), None
patent: WO 94/02175 (1994-02-01), None
patent: WO 94/04679 (1994-03-01), None
patent: WO 94/08620 (1994-04-01), None
patent: WO 94/12214 (1994-06-01), None
patent: WO 96/32478 (1996-10-01), None
patent: WO 97/26912 (1997-07-01), None
Aversano et al., “A Chimeric IgG4 Monoclonal Antibody Directed Against CD18 Reduces Infarct Size in a Primate Model of Myocardial Ischemia and Reperfusion”J. Amer. Col. Cardiology25 (3):781-788 (Mar. 1995).
Barron et al., “Use of reperfusion therapy for acute myocardial infarction in the United States: data from the National Registry of Myocardial Infarction 2”Circulation97(12):1150-1156 (Mar. 31, 1998).
Bednar et al., “Comparison of Triphenyltetrazolium Dye with Light Microscopic Evaluation in a Rabbit Model of Acute Cerebral Ischaemia”Neurological Research16:129-132 (Apr. 1994).
Bednar et al., “IB4, a Monoclonal Antibody Against the CD18 Adhesion Complex of Leukocytes, Attenuates Intracranial Hypertension in a Rabbit Stroke Model”Stroke(Abstract Only) 23(1):152 (1992).
Bednar et al., “IB4, a monoclonal antibody against the CD18 leukocyte adhesion protein, reduces intracranial pressure following thromboembolic stroke in the rabbit”Neurological Res. 18:171-175 (Apr. 1996).
Bednar et al., “The Role of Neutrophils and Platelets in a Rabbit Model of Thromboembolic Stroke”Stroke22(1):44-50 (1991).
Bose et al., “Evolving Focal Cerebral Ischemia in Cats: Spatial Correlation of Nuclear Magnetic Resonance Imaging, Cerebral Blood Flow, Tetrazolium Staining, and Histopathology”Stroke19(1):28-37 (Jan. 1988).
Bowes et al., “Monoclonal Antibodies Preventing Leukocyte Activation Reduce Experimental Neurologic Injury and Enhance Efficacy of Thrombolytic Therapy”Neurology45:815-819 (1995).
Bowes et al., “Monoclonal Antibody to the ICAM-1 Adhesion Site Reduces Neurological Damage in a Rabbit Cerebral Embolism Stroke Model”Experimental Neurology119(2):215-219 (1993).
Chen et al., “Anti-CD11b Monoclonal Antibody Reduce Ischemic Cell Damage After Transient Focal Cerebral Ischemia in Rat Anti-CD11b Monoclonal Antibody Reduces Ischemic Cell Damage After Transient Focal Cerebral Ischemia in Rat”Ann. Neurol. 35(4):458-463 (1994).
Chen et al., “Neutropenia Reduces The Volume of Cerebral Infarct After Transient Middle Cerebral Artery Occulsion in the Rat”Neuroscience Research Communications11(2):93-99 (1992).
Chopp et al., “Anti-CD11b Monoclonal Antibody (1B6c) Reduces Infarct Size Resulting From Transient but Not Permanent Focal Ischemia in Rat”Stroke(Abstract Only) (19th International J), Stroke 25(1): p. 267, 1994.
Chopp et al., “Postischemic Administration of an Anti-MAC-1 Antibody Reduces Ischemic Cell Damage After Transient Middle Cerebral Artery Occlusion in Rats”Stroke25(4):869-876 (1993).
Chopp et al., “The clot thickens—thrombolysis and combination therapies”Acta Neurochirurgica73 (Suppl.):67-71 (1999).
Clark et al., “Reduction of Central Nervous System Ischemic Injury by Monoclonal Antibody to Intercellular Adhesion Molecule”J. Neurosurg. 75:623-627 (1991).
Clark et al., “Reduction of Central Nervous System Ischemic Injury in Rabbits Using Leukocyte Adhesion Antibody Treatment”Stroke22(7):877-883 (Jul. 1991).
Clark et al., “Reperfusion Following Focal Stroke Hastens Inflammation and Resolution of Ischemic Injured Tissue”Brain Research Bulletin35(4):387-392 (1994).
Danilenko et al., “A Novel Canine Leukointegrin, αdβ2, is Expressed by Specific Macrophage Subpopulations in Tissue and a Minor CD8+Lymphocyte Subpopulation in Peripheral Blood”Journal of Immunology155:35-44 (1995).
del Zoppo et al., “Polymorphonuclear Leukocytes Occlude Capillaries Following Middle Cerebral Artery Occlusion and Reperfusion in Baboons”Stroke22(10):1276-1283 (1991).
Desroches et al., “Regulation and Functional Involvement of Distinct Determinants of Leucocyte Function-Associated Antigen 1 (LFA-1) in T-Cell Activation In Vitro”Scand. J. Immunol. 33:277-286 (1991).
Eigenbrot et al., “X-Ray Structures of Fragments From Binding and Nonbinding Versions of a Humanized Anti-CD18 Antibody: Structural Indications of the Key Role of VHResidues 59 to 65”Proteins: Structure, Function, and Genetics18:49-62 (1994).
Fekete et al., “Involvement of Lymphocyte Function-Associated Antigen-1 (LFA-1) But Not ICAM-1 in a Radioactive Leukocyte Cell-Mediated Immunity (LA-CMI) Assay”J. Clin. Lab. Immunol. 31:145-149 (1990).
Fisher et al., “The Penumbra, Therapeutic Time Window and Acute Ischaemic Stroke”Bailliere's Clinical Neurology4(2):279-295 (Aug. 1995).
Garcia, “Effects of CD11b/18 Monocloan Antibody on Rats with Permanent Middle Cerebral Artery Occlusion”Amer. J. Pathology148(1):241-248 (Jan. 1996).
Gross et al., “Delayed Tissue-Plasminogen Activator Therapy in a Rabbit Model of Thromoembolic Stroke”Neurosurgery36(6):1172-1177 (1995).
Gross et al., “Transforming Growth Factor-β1 Reduces Infarct Size After Experimental Cerebral Ischemia in a Rabbit Model”Stroke24(4):558-562 (Apr. 1993).
Hildreth & Hyman, “Production and characterization of Monoclonal Anti-CD18 Anti-Idiotype Antibodies”Molecular Immunology26(12):1155-1167 (1989).
Hildreth et al., “A Human Lymphoctye-associated Antigen Involved in Cell-mediated Lympholysis”European Journal of Immunology13:202-208 (1983).
Hutchings et al., “Transfer of Diabetes in Mice Prevented by Blockade of Adhesion-Promoting Receptor on Macrophages”Nature348:639-642 (Dec. 13, 1990).
Jiang et al., “Anti-CD11b Monoclonal Antibody Reduces Ischemic Cell Damage After Transient (2h) But Not After Permanent MCA Occlusion in the Rat”Neuroscience Research Communications15(2):85-93 (1994).
Jones et al., “Thresholds of Focal Cerebral Ischemia in Awake Monkeys”Journal of Neurosurgery54:773-782 (Jun. 1981).
Kim et al., “Adhesive Glycoproteins CD11a are Upregulated in the Leukocytes from Patients with Ischemic Stroke and Transient Ischemic Attacks”Journal of the Neurological Sciences128(1):45-50 (1995).
Kohut et al., “Reduction in Ischemic Brain Injury in Rabbits by the Anion Transport Inhibitor L-644, 711”Stroke23(1):93-97 (Jan. 1992).
Kumar et al., “Recombinant soluble form of PSGL-1 accelerates thrombolysis and prevents reocclusion in a porcine model”Circulation99(10):1363-1369 (Mar. 16, 1999).
Lew et al., “Complement depletion does not reduce brain injury in a rabbit model of thromboembolic stroke”Brain Research Bulletin48(3):325-331 (Fe
Bednar Martin M.
Gross Cordell E.
Gross, legal representative Linda J.
Thomas G. Roger
Dreger Ginger R.
Evans David W.
Fox James A.
Gambel Phillip
Genentech Inc.
LandOfFree
Co-administration of a tissue plasminogen activator,... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Co-administration of a tissue plasminogen activator,..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Co-administration of a tissue plasminogen activator,... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4216591